Cabaletta Bio (CABA) News Today $2.75 +0.04 (+1.48%) (As of 12/17/2024 05:56 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measuresDecember 10, 2024 | finance.yahoo.comPoint72 Asset Management L.P. Makes New $3.15 Million Investment in Cabaletta Bio, Inc. (NASDAQ:CABA)Point72 Asset Management L.P. acquired a new position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 667,275 shares of the company's stock, valued at approxDecember 10, 2024 | marketbeat.comCabaletta Bio, Inc. (NASDAQ:CABA) Shares Bought by Walleye Capital LLCWalleye Capital LLC boosted its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 111.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 401,982 shares of the company's stock after buDecember 5, 2024 | marketbeat.comStock Traders Purchase High Volume of Call Options on Cabaletta Bio (NASDAQ:CABA)Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) was the target of some unusual options trading on Friday. Traders bought 3,715 call options on the company. This represents an increase of 1,730% compared to the typical volume of 203 call options.November 29, 2024 | marketbeat.comCabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Rating of "Buy" by AnalystsShares of Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) have been assigned an average rating of "Buy" from the ten brokerages that are currently covering the stock, MarketBeat Ratings reports. Ten research analysts have rated the stock with a buy rating. The average 12 month target price amoNovember 29, 2024 | marketbeat.comCabaletta Bio Presents Positive Data On CABA-201 At ACR Convergence 2024November 28, 2024 | nasdaq.comCabaletta Bio to Participate in Upcoming Investor Conferences in DecemberNovember 26, 2024 | markets.businessinsider.comCabaletta Bio Unveils Promising Data on CABA-201 at ACR Convergence 2024November 22, 2024 | msn.comCabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024November 20, 2024 | nasdaq.comCabaletta Bio Reports Q3 2024 Financial ResultsNovember 19, 2024 | markets.businessinsider.comCabaletta Bio Reveals CABA-201's Positive Clinical Safety And Efficacy DataNovember 18, 2024 | markets.businessinsider.comCabaletta Bio announces updated clinical data on CABA-201November 18, 2024 | markets.businessinsider.comCabaletta Bio’s Promising Expansion and Strategic Positioning Earns Buy RatingNovember 16, 2024 | markets.businessinsider.comCabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial AdvancementsNovember 16, 2024 | msn.comCabaletta Bio’s Promising Trial Results and Proactive Management Secure Buy RatingNovember 15, 2024 | markets.businessinsider.comCabaletta Bio (NASDAQ:CABA) Given New $12.00 Price Target at Wells Fargo & CompanyWells Fargo & Company dropped their price target on shares of Cabaletta Bio from $20.00 to $12.00 and set an "overweight" rating on the stock in a research note on Friday.November 15, 2024 | marketbeat.comCabaletta Bio (NASDAQ:CABA) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $25.00 target price on shares of Cabaletta Bio in a research note on Friday.November 15, 2024 | marketbeat.comCabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 14, 2024 | markets.businessinsider.comCabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim’s Healthcare Innovation Conference!November 8, 2024 | msn.comCabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation ConferenceNovember 6, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Cabaletta Bio (CABA)November 6, 2024 | markets.businessinsider.comCabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by AnalystsShares of Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) have been given a consensus rating of "Buy" by the ten analysts that are covering the firm, Marketbeat Ratings reports. Ten research analysts have rated the stock with a buy recommendation. The average 1-year target price among analystsNovember 4, 2024 | marketbeat.comWe're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn RateOctober 30, 2024 | finance.yahoo.comCabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Down 28.9% in OctoberCabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) was the target of a large decline in short interest in October. As of October 15th, there was short interest totalling 3,780,000 shares, a decline of 28.9% from the September 30th total of 5,320,000 shares. Based on an average daily trading volume, of 1,040,000 shares, the short-interest ratio is presently 3.6 days.October 28, 2024 | marketbeat.comCabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of CashOctober 22, 2024 | seekingalpha.comShort Interest in Cabaletta Bio, Inc. (NASDAQ:CABA) Declines By 16.7%Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) was the recipient of a large decline in short interest in September. As of September 30th, there was short interest totalling 5,320,000 shares, a decline of 16.7% from the September 15th total of 6,390,000 shares. Based on an average daily volume of 1,050,000 shares, the short-interest ratio is currently 5.1 days.October 14, 2024 | marketbeat.comUBS Initiates Coverage of Cabaletta Bio (CABA) with Buy RecommendationOctober 12, 2024 | msn.comMillennium Management LLC Grows Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA)Millennium Management LLC grew its holdings in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 24.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 698,317 shares of the company's stock after purchasOctober 12, 2024 | marketbeat.comKyverna, Cabaletta started at buys by UBS on CAR T therapy potentialOctober 10, 2024 | msn.comCabaletta Bio (NASDAQ:CABA) Coverage Initiated at UBS GroupUBS Group began coverage on Cabaletta Bio in a research report on Thursday. They issued a "buy" rating and a $10.00 price objective on the stock.October 10, 2024 | marketbeat.comCabaletta Bio (NASDAQ:CABA) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comCabaletta Bio (NASDAQ:CABA) Stock, Insider Trading ActivityOctober 7, 2024 | benzinga.comCabaletta Bio, Inc. (NASDAQ:CABA) Position Boosted by Squarepoint Ops LLCSquarepoint Ops LLC raised its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 643.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 315,379 shares of the company's stock after buOctober 4, 2024 | marketbeat.comCabaletta Bio secures lease terms through August 2026October 2, 2024 | investing.comPerceptive Advisors LLC Cuts Position in Cabaletta Bio, Inc. (NASDAQ:CABA)Perceptive Advisors LLC trimmed its holdings in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 65.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 585,045 shares of the company's stock after selling 1,131,615September 30, 2024 | marketbeat.comLynx1 Capital Management LP Lowers Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA)Lynx1 Capital Management LP reduced its stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 76.4% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 492,103 shares of the company's stock after selling 1,590,870September 27, 2024 | marketbeat.comCabaletta Bio to Present Key Findings on CABA-201 at ACR Convergence 2024September 27, 2024 | msn.comStifel Nicolaus Remains a Buy on Cabaletta Bio (CABA)September 26, 2024 | markets.businessinsider.comDeerfield Management Company L.P. Series C Reduces Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA)Deerfield Management Company L.P. Series C decreased its holdings in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 63.1% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 464,252 shares of the company's stock after selling 794,398 sharesSeptember 26, 2024 | marketbeat.comCabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024September 25, 2024 | globenewswire.comE Fund Management Co. Ltd. Buys 269,675 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA)E Fund Management Co. Ltd. grew its stake in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 1,610.1% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 286,424 shares of the company's stock aftSeptember 18, 2024 | marketbeat.comCabaletta Bio’s Strategic Advancements Garner Buy Rating from Douglas TsaoSeptember 17, 2024 | markets.businessinsider.comCabaletta Bio (NASDAQ:CABA) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $25.00 price target on shares of Cabaletta Bio in a report on Tuesday.September 17, 2024 | marketbeat.comSofinnova Investments Inc. Boosts Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA)Sofinnova Investments Inc. increased its holdings in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 184.0% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,220,400 shares of the company's stock after purchasing an additional 790,65September 17, 2024 | marketbeat.comShort Interest in Cabaletta Bio, Inc. (NASDAQ:CABA) Decreases By 28.4%Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) was the target of a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 6,280,000 shares, a drop of 28.4% from the July 31st total of 8,770,000 shares. Based on an average trading volume of 1,300,000 shares, the short-interest ratio is currently 4.8 days.August 31, 2024 | marketbeat.comPanagora Asset Management Inc. Takes $2.24 Million Position in Cabaletta Bio, Inc. (NASDAQ:CABA)Panagora Asset Management Inc. purchased a new stake in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 299,801 shares of the company's stock, valued at approximately $2,243,00August 31, 2024 | marketbeat.comCabaletta Bio, Inc. Set to Engage at Key Investor ConferencesAugust 29, 2024 | msn.comCabaletta Bio to Participate in Upcoming Investor Conferences in SeptemberAugust 28, 2024 | globenewswire.comSeveral Headwinds Dragged Cabaletta Bio (CABA) in Q2August 21, 2024 | msn.comCabaletta Bio, Inc. (NASDAQ:CABA) Given Average Rating of "Buy" by BrokeragesShares of Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) have been given an average rating of "Buy" by the nine ratings firms that are presently covering the stock, Marketbeat.com reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among anAugust 21, 2024 | marketbeat.com Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address DeFi Coin on Verge of Breakout! (Ad)[FREE BOOK] Can You Make a Fortune in Crypto with $50? Get started now before the market takes off! Click here to request your free copy NOW! CABA Media Mentions By Week CABA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CABA News Sentiment▼0.390.79▲Average Medical News Sentiment CABA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CABA Articles This Week▼13▲CABA Articles Average Week Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HUMA News Today MREO News Today PRTC News Today CRMD News Today ANAB News Today XERS News Today RNAC News Today MGTX News Today ABVX News Today GLUE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CABA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
